@article{63a1bc056ca141e8aee96224a6395270,
title = "Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B",
abstract = "Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust humoral and cellular immune responses and completely protected the vaccinated animals from SARS-CoV-2 infection in the lung. Studies in hamsters also showed that PTX-COVID19-B protected the upper respiratory tract from SARS-CoV-2 infection. Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages. No adverse effects were induced by PTX-COVID19-B in either mice or hamsters. Based on these results, PTX-COVID19-B was authorized by Health Canada to enter clinical trials in December 2020 with a phase 2 clinical trial ongoing.",
author = "Jun Liu and Patrick Budylowski and Reuben Samson and Griffin, {Bryan D.} and Giorgi Babuadze and Bhavisha Rathod and Karen Colwill and Abioye, {Jumai A.} and Schwartz, {Jordan A.} and Ryan Law and Lily Yip and Ahn, {Sang Kyun} and Serena Chau and Maedeh Naghibosadat and Yuko Arita and Queenie Hu and Yue, {Feng Yun} and Arinjay Banerjee and Hardy, {W. Rod} and Karen Mossman and Samira Mubareka and Kozak, {Robert A.} and Pollanen, {Michael S.} and Orozco, {Natalia Martin} and Gingras, {Anne Claude} and Marcusson, {Eric G.} and Ostrowski, {Mario A.}",
note = "Funding Information: This work was funded by the National Research Council of Canada-Industrial Research Assistance Program (NRC-IRAP) to Providence Therapeutics Holdings Inc.; Canadian Institutes of Health Research (to M.A.O.); Ontario HIV Treatment Network (to M.A.O.); Li Ka Shing Knowledge Institute (to M.A.O.); Juan and Stefania Speck fund for COVID-19 and other virus infections (to M.A.O.); Canadian Institutes of Health Research VRI-172711 (to A.-C.G.); Canadian Institutes of Health Research, Canada Research Chair, Tier 1, in Functional Proteomics (to A.-C.G.); Krembil Foundation and Royal Bank of Canada to the Sinai Health System Foundation (to A.-C.G.); Coronavirus Variants Rapid Response Network (to A.-C.G.); Canadian Institutes of Health Research (to K.M.); Canadian Institutes of Health Research (to A.B.); and Natural Sciences and Engineering Research Council of Canada (to A.B.). Publisher Copyright: Copyright {\textcopyright} 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).",
year = "2022",
month = jan,
doi = "10.1126/sciadv.abj9815",
language = "English (US)",
volume = "8",
journal = "Science Advances",
issn = "2375-2548",
publisher = "American Association for the Advancement of Science",
number = "3",
}